Table 2. Clinical relevance of detected genetic alterations.
| Patients with genetic alterations | All, n=432 (%) | 2019, n=189 (%) | 2020, n=243 (%) | P value |
|---|---|---|---|---|
| Alteration detected (all) | 364 (84.3) | 163 (86.2) | 201 (82.7) | 0.353 |
| Targetable alteration detected | 82 (19.0) | 35 (18.5) | 47 (19.3) | 0.902 |
| In early stage (I−IIIA) | 36 (8.3) | 17 (9) | 19 (7.8) | 0.727 |
| In late stage (IIIB−IV) | 40 (9.3) | 16 (8.5) | 24 (9.9) | 0.738 |
| In recurrent tumor | 6 (1.4) | 2 (1.1) | 4 (1.6) | 0.7 |
| With co-alteration (all) | 51 (11.8) | 26 (13.8) | 25 (10.3) | 0.294 |
| With targetable co-alteration | 7 (1.6) | 3 (1.6) | 4 (1.6) | >0.9999 |
| Targeted therapy received (all) | 38 (8.8) | 14 (7.4) | 24 (9.9) | 0.397 |
| In early stage (I−IIIA) | 3 (0.7) | 2 (1.1) | 1 (0.4) | 0.584 |
| In late stage (IIIB−IV) | 29 (6.7) | 10 (5.3) | 19 (7.8) | 0.337 |
| In recurrent tumor | 6 (1.4) | 2 (1.1) | 4 (1.6) | 0.7 |
| Therapy based on detected mutation1 | 27 (6.3) | 12 (6.3) | 15 (6.2) | >0.9999 |
| Osimertinib | 19 (4.4) | 9 (4.8) | 10 (4.1) | 0.815 |
| Afatinib | 11 (2.5) | 5 (2.6) | 6 (2.5) | >0.9999 |
| Trametinib/Dabrafenib | 4 (0.9) | 2 (1.1) | 2 (0.8) | >0.9999 |
| Gefitinib | 2 (0.5) | 2 (1.1) | 0 (0) | 0.191 |
| Mobocertinib | 1 (0.2) | 0 (0) | 1 (0.4) | >0.9999 |
| Therapy based on detected fusion/skipping1 | 11 (2.5) | 2 (1.1) | 9 (3.7) | 0.123 |
| Alectinib | 6 (1.4) | 0 (0) | 6 (2.5) | 0.038 |
| Brigatinib | 4 (0.9) | 0 (0) | 4 (1.6) | 0.135 |
| Selpercatinib | 3 (0.7) | 0 (0) | 3 (1.2) | 0.26 |
| Capmatinib | 1 (0.2) | 1 (0.5) | 0 (0) | 0.438 |
| Lorlatinib | 1 (0.2) | 1 (0.5) | 0 (0) | 0.438 |
| Emerging biomarker2 detected | 72 (16.7) | 30 (15.9) | 42 (17.3) | 0.795 |
| In early stage (I−IIIA) | 29 (6.7) | 15 (7.9) | 14 (5.8) | 0.439 |
| In late stage (IIIB−IV) | 38 (8.8) | 13 (6.9) | 25 (10.3) | 0.235 |
| In recurrent tumor | 5 (1.2) | 2 (1.1) | 3 (1.2) | >0.9999 |
Results of both subgroups (patients from 2019 and 2020, respectively) were compared using Fisher’s exact test. 1, some patients received more than one substance; 2, NRG1 fusion, KRAS G12C, ERBB2, FGFR1 [according to (10)].